Rituximab in autologous stem cell transplantation for follicular lymphoma

Anti-Cancer Drugs

Volumn 12, Issue SUPPL. 2, 2001, Pages

  Schmitz, N ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

Follicular lymphoma; Rituximab; Stem cell transplantation

Indexed keywords

CD20 ANTIGEN; CD34 ANTIGEN; MONOCLONAL ANTIBODY; PROTEIN BCL 2; RITUXIMAB;

AUTOTRANSPLANTATION; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; FOLLICULAR LYMPHOMA; GENE TRANSLOCATION; INFUSION; LEUKEMIA REMISSION; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RELAPSE; SALVAGE THERAPY; STEM CELL; STEM CELL TRANSPLANTATION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, FOLLICULAR; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME;

EID: 0034959831     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (31)

1. The natural history of initially untreated low-grade non-Hodgkin's lymphomas
2. Patterns of survival in patients with recurrent follicular lymphoma: A 20-year study from a single center
3. A pilot study on the use of the ProMACE-CytaBOM regimen as a first-line treatment of advanced follicular non-Hodgkin's lymphoma
4. The treatment of indolent lymphomas: Watchful waiting versus aggressive combined modality treatment
5. Fludarabine versus conventional CVP chemotherapy in newly diagnosed patients with stages III and IV low grade non-Hodgkin's lymphoma. Preliminary results from a prospective randomized phase III clinical trial in 381 patients
6. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma
7. Sequential high-dose therapy with peripheral-blood progenitor-cell support in low-grade non-Hodgkin's lymphoma
8. High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma
9. Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma
10. Autologous stem-cell transplantation for non-Hodgkin's lymphomas: The role of graft purging and radiotherapy posttransplantation - Results of a retrospective analysis on 120 patients autografted in a single institution
11. High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma
12. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients
13. Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma
14. High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: Long-term clinical and molecular follow-up
15. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma
16. The CUP trial: A randomized study analyzing the efficacy of high dose therapy and purging in low-grade non-Hodgkin's lymphoma (NHL)
17. Correlation of bcl-2 rearrangement with clinical characteristics and outcome in indolent follicular lymphoma
18. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
19. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy
20. IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma
21. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study
22. Expression of human B-cell-associated antigens on leukemias and lymphomas: A model of human B-cell differentiation
23. Rapid and complete hemopoietic reconstitution following combined transplantation of autologous blood and bone marrow cells. A changing role for high dose chemo-radiotherapy?
24. Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte stimulating factor
25. Peripheral blood stem cell mobilization for high-dose chemotherapy
26. In vivo purging with rituximab during stem cell transplantation for indolent lymphoma
27. Stem cell function and engraftment is not affected by 'in vivo purging' with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma
28. In vivo purging with rituximab before autologous peripheral blood progenitor cell (PBPC) transplantation in lymphoma patients (pts)
29. In vivo depletion of B-cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma
30. Mobilization of peripheral stem cells in patients with indolent lymphoma using a combination of MINE with rituximab
31. Consolidative immunotherapy with rituxan in autologous stem cell transplantation in follicular lymphoma is associated with molecular remissions